Latest news

New! Olink proteomics joins the dance of our biomarker discovery capacities

05 / 31 / 2022

New! Olink proteomics joins the dance of our biomarker discovery capacities

As Olink®-certified service Provider, Explicyte offers now high proteomic analysis capabilities for comprehensive protein biomarker discovery using Olink® Target technology.

Olink®’s Target96 biomarker panels are dedicated to many diseases and/or biological processes. You can directly download them from the form below and do not hesitate to let us know your proteomics projects!

Pembrolizumab in soft-tissue sarcomas with tertiary lymphoid structures: a phase 2 PEMBROSARC trial cohort

05 / 26 / 2022

Pembrolizumab in soft-tissue sarcomas  with tertiary lymphoid structures: a phase 2  PEMBROSARC trial cohort

Nature medicine, 2022, May 26
A. Italiano , A. Bessede, M. Pulido, E. Bompas , S. Piperno-Neumann, C. Chevreau, N. Penel, F. Bertucci, M. Toulmonde, C. Bellera, J. P. Guegan, C. Rey, C. Sautès-Fridman , A. Bougoüin, C. Cantarel, M. Kind, M. Spalato, B. Dadone-Montaudie, F. Le Loarer, J. Y. Blay  and W. H. Fridman

Gearing up for ASCO 2022 event! Meet Explicyte in Chicago!

05 / 19 / 2022

Gearing up for ASCO 2022 event! Meet Explicyte in Chicago!

From June 3 to 7, 2022, we will be setting up our quarters in Chicago for the American Society of Clinical Oncology Annual Meeting to continue gaining the latest insights in research and clinical development in Oncology. Also, our CEO Dr. Alban Bessede will have the great opportunity to present a scientific poster highlighting our recent advances in biomarker research in Immuno-Oncology.

Spotlight on our in vivo advances

05 / 12 / 2022

Spotlight on our in vivo advances

Development and characterization of a novel anti-PD1 resistant sarcoma mouse model

Soft Tissue Sarcoma (STS) is known to be refractory to current cancer immunotherapies including the PD1 immune checkpoint inhibitor (ICI) (Toulmonde et al., 2018), thus claiming the development of novel therapeutic strategies aiming at improving the current clinical benefit.

It’s time to download our posters presented at AACR 2022!

04 / 21 / 2022

It’s time to download our posters presented at AACR 2022!

Back from the AACR 2022, it was a pleasure to take part in it and to converse about our posters showcasing our newest preclinical and translational research advances in Immuno-Oncology.

If you didn't get the chance to meet us and see our posters, or if you want to review them, you can directly download them from the form below.

We'll be there! Meet Explicyte at AACR event in New Orleans

03 / 29 / 2022

We'll be there! Meet Explicyte at AACR event in New Orleans

We will be attending the AACR Annual Meeting in New Orleans, from April 8 to 13, 2022. We will be glad to take this opportunity to meet you there,  approach your research projects and introduce our service offerings. We will also presentsome scientific posters to highlight our latest innovative preclinical and translational research advances.